Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-01-06
2010-02-02
Allen, Marianne P (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900
Reexamination Certificate
active
07655762
ABSTRACT:
Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
REFERENCES:
patent: 7371384 (2008-05-01), Gerber et al.
patent: WO 99/67382 (1999-12-01), None
patent: WO 01/77151 (2001-10-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 2006/014678 (2006-02-01), None
patent: WO 2006/014729 (2006-02-01), None
Yoshida, K. et al., Journal of Lipid Research, 43:1770-1772, 2002.
Ando et al., “A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice,”J. Lipid Res., 44:1216-1223 (2003).
Chait et al., “Chylomicronemia syndrome,”Adv. Intern. Med., 37:249-273 (1992).
Ge et al., “Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4,”J. Biol. Chem., 279:2038-2045 (2004).
Ge et al., “Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4,”J. Lipid Res., 45:2071-2079 (2004).
Ge et al., “Differential regulation and properties of angiopoietin-like proteins 3 and 4,”J. Lipid Res., 46:1484-1490 (2005).
Hermann et al., “Angiopoietin-like-4 is a potential angiogenic mediator in arthritis,”Clinical Immunology, 115:93-101(2005).
Kersten et al., “Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene,”J. Biol. Chem., 275:28488-28493 (2000).
Kersten, “Regulation of lipid metabolism via angiopoietin-like proteins,”Biochemical Society Transactions, 33:1059-1062 (2005).
Kim et al., “Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis,”Biochem. J., 346:603-610 (2000).
Koishi et al., “AngptI3regulates lipid metabolism in mice,”Nature Genetics, 30:151-157 (2002).
Korstanje et al., “LocatingAth8, a locus for murine atherosclerosis susceptibility and testing several of its candidate genes in mice and humans,”Atherosclerosis, 177:443-450 (2004).
Köster et al., “Transgenic AngptI4 overexpression and targeted disruption of AngptI4 and Angptl3: regulation of triglyceride metabolism,”Endocrinology, Published online Aug. 4, 2005, as doi:10.1210/en.2005-0476.
Kratky et al., “Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase—deficient mouse adipose tissue,”J. Clin. Invest., 115:161-167 (2005).
Mandard et al., “The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment,”J. Biol. Chem., 279:34411-34420 (2004).
Mandard et al., “The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity,”JBC Papers in Press, published Nov. 4, 2005 www.ibc.org/cgi/doi/10.1074/jbc.M506519200.
Moller, “New drug targets for type 2 diabetes and the metabolic syndrome,”Nature, 414:821-827 (2001).
Nishimura et al., “Effects of NO-1886 (lbrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes,”Drug Meta. Pharmacokinet., 19:422-429 (2004).
Oike et al., “Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy,”Trends in Molecular Medicine, Article in Press (2005) doi:10.1016/j.molmed.2005.08.002.
Schuetz et al., “Molecular classification of renal tumors by gene expression profiling,”J. Mol. Diagn., 7:206-218 (2005).
Sharkey et al., “Novel antiangiogenic agents for use in contraception,”Contraception, 71:263-271(2005).
Shimizugawa et al., “ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase,”J. Biol. Chem., 277:33742-33746 (2002).
Weinstock et al., “Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice,”J Clin Invest., 96:2555-2568 (1995).
Yin et al., “Lipoprotein lipase activator NO-1886,”Cardiovascular Drug Reviews, 21:133-142 (2003).
Yu et al., “Inhibition of cardiac lipoprotein utilization by transgenic overexpression of AngptI4 in the heart,”PNAS, 102:1767-1772 (2005).
International Nonproprietary Names for Pharmaceuticals Substances (INN),WHO Drug Information, 17:267-286 (2003).
Janeway et al.,Immunobiology, section 3-5, pp. 3:7 to 3:9 (Current Biology Ltd./Garland Publishing Inc. 1994).
Romeo et al., “Population-based resequencing ofANGPTL4uncovers variations that reduce triglycerides and increase HDL,”Nature Genetics, 39: 513-516 (2007).
Desai et al., “Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice,”Proc. Natl. Acad. Sci., 104:11766-11771 (2007).
Li, “Genetics and regulation of angiopoietin-like proteins 3 and 4,”Curr. Opin. Lipidol., 17: 152-156 (2006).
Sukonina et al., “Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue,”Proc. Natl. Acad. Sci., 103:17450-17455 (2006).
Yoshida et al., “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase,”J. Lipid Res., 43:1770-1772 (2002).
Chen Ling
Chung Kyu
Desai Urvi
Hong Seokjoo
Landes Gregory M.
Allen Marianne P
Lexicon Pharmaceuticals, Inc.
Michael & Best & Friedrich LLP
LandOfFree
Monoclonal antibodies against ANGPTL4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against ANGPTL4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against ANGPTL4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182210